Fast Track Designation for LP-184 (STAR-001) recognizes Glioblastoma (GBM) as a serious condition impacting more than 13,000 ...
Aerovate Therapeutics (AVTE) and Jade Biosciences announced that they have entered into a definitive merger agreement for an all-stock ...
GlycoMimetics (GLYC) announced it has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company.
Every year at the Pediatric Hospital Medicine (PHM) conference, the top 10 publications from the PHM literature are selected ...
Despite the prevalence of Lp(a) and its impact on cardiovascular health ... at 07:05 Imvax to Present Safety Data on Lead Program, IGV-001, at 2024 SNO Annual Meeting Imvax, Inc., a clinical-stage ...
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of $3.65 ...
Canada stocks were lower after the close on Tuesday, as losses in the Clean Technology, Utilities and Telecoms sectors led ...
About CER-001 CER-001 is an engineered HDL particle which ... such as lipopolysaccharide (LPS), with the ability to inactivate LPS and target it for removal by the liver. In addition, its ...
Through Lantern's wholly-owned subsidiary Starlight Therapeutics, LP-184 (designated as STAR-001 for CNS indications) is being positioned for a Phase 1b/2a clinical trial in recurrent GBM that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback